Pretreatment patient characteristics
| Characteristic . | Value . |
|---|---|
| Patients, N | 35 |
| Median age, y (range) | 53 (21-79) |
| Median WBC, ×109/L (range) | 17.4 (1.7-284.3) |
| Performance status | |
| 0-1 | 33 (94) |
| 2 | 2 (6) |
| CNS disease at start | 4 (11) |
| Cytogenetics | |
| Ph+ | 9 (25) |
| Ph+ plus other | 24 (69) |
| IM/ND (BCR-ABL+) | 2 (6) |
| Molecular | |
| e1a2 or e1a3 | 25 (71) |
| e13a2/e14a2 | 9 (26) |
| Unknown | 1 (3) |
| CD20 expression ≥20% | 17 (49) |
| Characteristic . | Value . |
|---|---|
| Patients, N | 35 |
| Median age, y (range) | 53 (21-79) |
| Median WBC, ×109/L (range) | 17.4 (1.7-284.3) |
| Performance status | |
| 0-1 | 33 (94) |
| 2 | 2 (6) |
| CNS disease at start | 4 (11) |
| Cytogenetics | |
| Ph+ | 9 (25) |
| Ph+ plus other | 24 (69) |
| IM/ND (BCR-ABL+) | 2 (6) |
| Molecular | |
| e1a2 or e1a3 | 25 (71) |
| e13a2/e14a2 | 9 (26) |
| Unknown | 1 (3) |
| CD20 expression ≥20% | 17 (49) |
Values are n (%) unless otherwise indicated.
WBC indicates white blood cell count; IM, insufficient metaphases; and ND, not done.